Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
11:45am, Wednesday, 07'th May 2025
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
11:31pm, Tuesday, 06'th May 2025
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say
07:00pm, Tuesday, 06'th May 2025
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
06:10pm, Tuesday, 06'th May 2025
Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago.
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
04:01pm, Tuesday, 06'th May 2025
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
10:15am, Monday, 05'th May 2025
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
05:00pm, Wednesday, 30'th Apr 2025
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:08am, Thursday, 24'th Apr 2025
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Tuesday, 22'nd Apr 2025
NOVATO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
09:49am, Wednesday, 16'th Apr 2025
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
10:30am, Thursday, 10'th Apr 2025
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
BROAD ARROW ADDS RARE RUF CTR YELLOWBIRD TO PORSCHE AUCTION IN PARTNERSHIP WITH AIR|WATER
12:46pm, Wednesday, 09'th Apr 2025
Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, has announced an exceedingly rare 1989 RUF CTR Yellowbird, chassis no. W09BT0348KPR06023, to lead its second annual Porsche Auction in partnershi
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 19'th Mar 2025
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Ultragenyx to Participate at Investor Conferences in March
04:30pm, Monday, 24'th Feb 2025
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 19'th Feb 2025
NOVATO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
